BERLIN, April 11 /PRNewswire-FirstCall/ -- Schering AG, Germany announced today that Detlef Olufs (63) was appointed to the Supervisory Board of Schering AG on April 7, 2006 by the local district court in Berlin-Charlottenburg.
Detlef Olufs succeeds Hermann-Josef Lamberti, who resigned from the Supervisory Board of Schering AG on March 20, 2006 due to his affiliation with the Deutsche Bank, which supported Merck KGaA in their takeover offer for Schering AG.
Detlef Olufs, who is a tax lawyer, studied law in Gottingen and Vienna. Before he joined the law firm Haarmann, Hemmelrath & Partner in 1991, he worked in the tax department of Schering AG for more than ten years. In 2006, Olufs became Managing Partner of the law firm Salans LLP and manages their Berlin branch office.
Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Gynecology&Andrology, Oncology, Diagnostic Imaging as well as Specialized Therapeutics for disabling diseases. As a global player with innovative products, Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life: making medicine work
This press release has been published by Corporate Communication of Schering AG, Berlin, Germany.
Your contacts at Corporate Communication:
Media Relations: Oliver Renner , T: +49-30-468-124-31, oliver.renner@schering.de
Investor Relations: Peter Vogt, T: +49-30-468-128-38, peter.vogt@schering.de
Find additional information at: www.schering.de/eng
At an appropriate time, Schering Aktiengesellschaft will file a solicitation/recommendation statement with the U.S. Securities and Exchange Commission relating to any tender offer for the ordinary shares or American Depositary Shares of Schering Aktiengesellschaft. Holders of ordinary shares and American depositary shares of Schering Aktiengesellschaft are advised to read such solicitation/recommendation statement when it becomes available because it will contain important information. Holders of ordinary shares and American depositary shares of Schering Aktiengesellschaft will be able to obtain such solicitation/recommendation statement and other filed documents when they become available free of charge at the U.S. Securities and Exchange Commission's website (http://www.sec.gov) and at Schering Aktiengesellschaft's website (http://www.schering.de).
Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.
Schering AGCONTACT: Your contacts at Corporate Communication: Media Relations: OliverRenner , T: +49-30-468-124-31, oliver.renner@schering.de. InvestorRelations: Peter Vogt, T: +49-30-468-128-38, peter.vogt@schering.de
